A novel 3p22.3 gene CMTM7 represses oncogenic EGFR signaling and inhibits cancer cell growth

Oncogene

Volumn 33, Issue 24, 2014, Pages 3109-3118

  Li, H ^a,b   Li, J ^c   Su, Y ^a   Fan, Y ^c   Guo, X ^a   Li, L ^c   Su, X ^c   Rong, R ^c   Ying, J ^d   Mo, X ^a   Liu, K ^a   Zhang, Z ^e   Yang, F ^b   Jiang, G ^b   Wang, J ^b   Zhang, Y ^a   Ma, D ^a   Tao, Q ^c   Han, W ^a  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d PEKING UNION MEDICAL COLLEGE   (China)

^e GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

3p22; CMTM7; LOH; methylation; tumor suppressor gene

Indexed keywords

CMTM7 PROTEIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; PROTEIN P27; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; CPG ISLAND; DOWN REGULATION; EPITHELIUM CELL; ESOPHAGEAL CANCER CELL LINE; G1 PHASE CELL CYCLE CHECKPOINT; GENE CLUSTER; GENE EXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IMMORTALIZED CELL LINE; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; METHYLATION; MOUSE; NASOPHARYNX CANCER; NONHUMAN; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; UPREGULATION;

MUS MUSCULUS;

ADULT; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHEMOKINES; CHROMOSOMES, HUMAN, PAIR 3; DNA METHYLATION; EPIGENESIS, GENETIC; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOENZYME TECHNIQUES; MARVEL DOMAIN-CONTAINING PROTEINS; MICE; MICE, NUDE; NEOPLASMS; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902475841     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.282     Document Type: Article

References (48)

1. Han W, Lou Y, Tang J, Zhang Y, Chen Y, Li Y et al. Molecular cloning and characterization of chemokine-like facto. 1 CKLF1), a novel human cytokine with unique structure and potential chemotactic activity. Biochem J 2001; 357(Pt 1): 127-135.
2. Han W, Ding P, Xu M, Wang L, Rui M, Shi S et al. Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics 2003; 81: 609-617.
3. Niu J, Li H, Zhang Y, Li J, Xie M, Li L et al. Aberrant expression of CKLF-like MARVEL transmembrane membe. 5 CMTM5) by promoter methylation in myeloid leukemia. Leuk Res 2010; 35: 771-776.
4. Li D, Jin C, Yin C, Zhang Y, Pang B, Tian L et al. An alternative splice form of CMTM8 induces apoptosis. Int J Biochem Cell Biol 2007; 39: 2107-2119.
5. Zhong J, Wang Y, Qiu X, Mo X, Liu Y, Li T et al. Characterization and expression profile of CMTM3/CKLFSF3. J Biochem Mol Biol 2006; 39: 537-545.
6. Wang Y, Zhang Y, Yang X, Han W, Liu Y, Xu Q et al. Chemokine-like facto. 1 is a functional ligand for CC chemokine recepto. 4 (CCR4). Life Sci 2006; 78: 614-621.
7. Shi S, Rui M, Han W, Wang Y, Qiu X, Ding P et al. CKLFSF2 is highly expressed in testis and can be secreted into the seminiferous tubules. Int J Biochem Cell Biol 2005; 37: 1633-1640.
8. Wang Y, Li T, Qiu X, Mo X, Zhang Y, Song Q et al. CMTM3 can affect the transcription activity of androgen receptor and inhibit the expression level of PSA in LNCaP cells. Biochem Biophys Res Commun 2008; 371: 54-58.
9. Wang Y, Li J, Cui Y, Li T, Ng KM, Geng H et al. CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res 2009; 69: 5194-5201.
10. Shao L, Cui Y, Li H, Liu Y, Zhao H, Wang Y et al. CMTM5 exhibits tumor suppressor activities and is frequently silenced by methylation in carcinoma cell lines. Clin Cancer Res 2007; 13: 5756-5762.
11. Guo X, Li T, Wang Y, Shao L, Zhang Y, Ma D et al. CMTM5 induces apoptosis of pancreatic cancer cells and has synergistic effects with TNF-alpha. Biochem Biophys Res Commun 2009; 387: 139-142.
12. Shao L, Guo X, Plate M, Li T, Wang Y, Ma D et al. CMTM5-v1 induces apoptosis in cervical carcinoma cells. Biochem Biophys Res Commun 2009; 379: 866-871.
13. Li H, Guo X, Shao L, Plate M, Mo X, Wang Y et al. CMTM5-v1, a four-transmembrane protein, presents a secreted form released via a vesicle-mediated secretory pathway. BMB Rep 2010; 43: 182-187.
14. Jin C, Wang Y, Han W, Zhang Y, He Q, Li D et al. CMTM8 induces caspasedependent and -independent apoptosis through a mitochondria-mediated pathway. J Cell Physiol 2007; 211: 112-120.
15. Li T, Zhong J, Chen Y, Qiu X, Zhang T, Ma D et al. Expression of chemokinelike facto. 1 is upregulated during T lymphocyte activation. Life Sci 2006; 79: 519-524.
16. Shao L, Li T, Mo X, Majdic O, Zhang Y, Seyerl M et al. Expressional and functional studies of CKLF1 during dendritic cell maturation. Cell Immunol 2010; 263: 188-195.
17. Plate M, Li T, Wang Y, Mo X, Zhang Y, Ma D et al. Identification and characterization of CMTM4, a novel gene with inhibitory effects on HeLa cell growth through Inducing G2/M phase accumulation. Mol Cells 2010; 29: 355-361.
18. Sanchez-Pulido L, Martin-Belmonte F, Valencia A, Alonso MA. MARVEL: a conserved domain involved in membrane apposition events. Trends Biochem Sci 2002; 27: 599-601.
19. Lind GE, Ahlquist T, Kolberg M, Berg M, Eknaes M, Alonso MA et al. Hypermethylated MAL gene - a silent marker of early colon tumorigenesis. J Transl Med 2008; 6: 13.
20. Buffart TE, Overmeer RM, Steenbergen RD, Tijssen M, van Grieken NC, Snijders PJ et al. MAL promoter hypermethylation as a novel prognostic marker in gastric cancer. Br J Cancer 2008; 99: 1802-1807.
21. Martin TA, Mansel RE, Jiang WG. Loss of occludin leads to the progression of human breast cancer. Int J Mol Med 2010; 26: 723-734.
22. Hu XT, Zhang FB, Fan YC, Shu XS, Wong AH, Zhou W et al. Phospholipase C delt. 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer. Oncogene 2009; 28: 2466-2475.
23. Ying J, Poon FF, Yu J, Geng H, Wong AH, Qiu GH et al. DLEC1 is a functional 3p22.3 tumour suppressor silenced by promoter CpG methylation in colon and gastric cancers. Br J Cancer 2009; 100: 663-669.
24. Sinha S, Singh RK, Alam N, Roy A, Roychoudhury S, Panda CK. Frequent alterations of hMLH1 and RBSP3/HYA22 at chromosomal 3p22.3 region in early and lateonset breast carcinoma: clinical and prognostic significance. Cancer Sci 2008; 99: 1984-1991.
25. Mao L, Fan YH, Lotan R, Hong WK. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines. Cancer Res 1996; 56: 5128-5131.
26. Sharp TV, Al-Attar A, Foxler DE, Ding L, de AVTQ, Zhang Y et al. The chromosome 3p21.3-encoded gene, LIMD1, is a critical tumor suppressor involved in human lung cancer development. Proc Natl Acad Sci USA 2008; 105: 19932-19937.
27. Qiu GH, Tan LK, Loh KS, Lim CY, Srivastava G, Tsai ST et al. The candidate tumor suppressor gene BLU, located at the commonly deleted region 3p21.3, is an E2F-regulated, stress-responsive gene and inactivated by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. Oncogene 2004; 23: 4793-4806.
28. Yi LoPH, Chung Leung AC, Xiong W, Law S, Duh FM, Lerman MI et al. Expression of candidate chromosome 3p21.3 tumor suppressor genes and down-regulation of BLU in some esophageal squamous cell carcinomas. Cancer Lett 2006; 234: 184-192.
29. Weinberg RA. Oncogenes and tumor suppressor genes. CA Cancer J Clin 1994; 44: 160-170.
30. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428.
31. Massague J. G1 cell-cycle control and cancer. Nature 2004; 432: 298-306.
32. Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 2004; 11: 689-708.
33. Odintsova E, Voortman J, Gilbert E, Berditchevski F. Tetraspanin CD82 regulates compartmentalisation and ligand-induced dimerization of EGFR. J Cell Sci 2003; 116(Pt 22): 4557-4566.
34. Collins BM, McCoy AJ, Kent HM, Evans PR, Owen DJ. Molecular architecture and functional model of the endocytic AP2 complex. Cell 2002; 109: 523-535.
35. Jin C, Ding P, Wang Y, Ma D. Regulation of EGF receptor signaling by the MARVEL domain-containing protein CKLFSF8. FEBS Lett 2005; 579: 6375-6382.
36. Bill HM, Knudsen B, Moores SL, Muthuswamy SK, Rao VR, Brugge JS et al. Epidermal growth factor receptor-dependent regulation of integrin-mediated signaling and cell cycle entry in epithelial cells. Mol Cell Biol 2004; 24: 8586-8599.
37. Brazil DP, Yang ZZ, Hemmings BA. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem Sci 2004; 29: 233-242.
38. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 2007; 10: 13-29.
39. Miyazaki A, Yogosawa S, Murakami A, Kitamura D. Identification of CMTM7 as a transmembrane linker of BLNK and the B-cell receptor. PLoS One 2012; 7: e31829.
40. Nakayama J, Yamamoto M, Hayashi K, Satoh H, Bundo K, Kubo M et al. BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3. Blood 2009; 113: 1483-1492.
41. Aviel-Ronen S, Coe BP, Lau SK, da Cunha Santos G, Zhu CQ, Strumpf D et al. Genomic markers for malignant progression in pulmonary adenocarcinoma with bronchioloalveolar features. Proc Natl Acad Sci USA 2008; 105: 10155-10160.
42. Ma S, Bao JY, Kwan PS, Chan YP, Tong CM, Fu L et al. Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma. Gastroenterology 2012; 143: 675-686 e671-612.
43. Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, Tsang YS et al. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 1999; 83: 121-126.
44. Cheng Y, Geng H, Cheng SH, Liang P, Bai Y, Li J et al. KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. Cancer Res 2010; 70: 6516-6526.
45. Li L, Ying J, Li H, Zhang Y, Shu X, Fan Y et al. The human cadherin 11 is a proapoptotic tumor suppressor modulating cell stemness through Wnt/beta-catenin signaling and silenced in common carcinomas. Oncogene 2012; 31: 3901-3912.
46. Tao Q, Huang H, Geiman TM, Lim CY, Fu L, Qiu GH et al. Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet 2002; 11: 2091-2102.
47. Tao Q, Swinnen LJ, Yang J, Srivastava G, Robertson KD, Ambinder RF. Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis. Am J Pathol 1999; 155: 619-625.
48. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987; 8: 138-140.